JP4210519B2 - 低免疫原性抗原の免疫原性を増強する医薬組成物 - Google Patents

低免疫原性抗原の免疫原性を増強する医薬組成物 Download PDF

Info

Publication number: JP4210519B2
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; vssp; composition according; ganglioside; outer membrane
Prior art date: 2000-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2002547529A

Other languages

English (en)

Japanese (ja)

Other versions

JP2004523494A (ja

JP2004523494A5 (de

JP2004523494A6 (ja

Inventor

モリーナ、ルイス、エンリケフェルナンデス

ラミレス、ベリンダサンチェス

ペスターナ、エデュアルド、ラウルスアレス

ラバルベラアイラ、アナベルデ

パルデーロ、シルセメサ

レオンデルガド、ホエルデ

ロドリゲス、イルディアンディアス

ロドリゲス、ロランドペレス

Original Assignee

セントロドインムノロジアモレキュラー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-06

Filing date

2001-12-06

Publication date

2009-01-21

2000-12-06 Priority claimed from CU20000285A external-priority patent/CU23000A1/es

2001-07-12 Priority claimed from CU20010167A external-priority patent/CU23009A1/es

2001-12-06 Application filed by セントロドインムノロジアモレキュラー filed Critical セントロドインムノロジアモレキュラー

2004-08-05 Publication of JP2004523494A publication Critical patent/JP2004523494A/ja

2005-05-26 Publication of JP2004523494A5 publication Critical patent/JP2004523494A5/ja

2005-06-30 Publication of JP2004523494A6 publication Critical patent/JP2004523494A6/ja

2009-01-21 Application granted granted Critical

2009-01-21 Publication of JP4210519B2 publication Critical patent/JP4210519B2/ja

2021-12-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000427 antigen Substances 0.000 title claims description 51
108091007433 antigens Proteins 0.000 title claims description 51
102000036639 antigens Human genes 0.000 title claims description 51
230000002163 immunogen Effects 0.000 title claims description 21
230000005847 immunogenicity Effects 0.000 title claims description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 15
230000002708 enhancing effect Effects 0.000 title claims description 5
229960005486 vaccine Drugs 0.000 claims description 72
150000002270 gangliosides Chemical class 0.000 claims description 45
108090000765 processed proteins & peptides Proteins 0.000 claims description 37
108090000623 proteins and genes Proteins 0.000 claims description 32
239000002671 adjuvant Substances 0.000 claims description 30
241000588650 Neisseria meningitidis Species 0.000 claims description 28
102000004169 proteins and genes Human genes 0.000 claims description 26
206010028980 Neoplasm Diseases 0.000 claims description 24
101710116435 Outer membrane protein Proteins 0.000 claims description 23
102000009465 Growth Factor Receptors Human genes 0.000 claims description 18
108010009202 Growth Factor Receptors Proteins 0.000 claims description 18
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
108020003175 receptors Proteins 0.000 claims description 16
102000005962 receptors Human genes 0.000 claims description 15
108010030416 proteoliposomes Proteins 0.000 claims description 14
229920001184 polypeptide Polymers 0.000 claims description 11
239000003725 proteoliposome Substances 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 10
230000036039 immunity Effects 0.000 claims description 7
208000014829 head and neck neoplasm Diseases 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
108091008606 PDGF receptors Proteins 0.000 claims description 5
230000002209 hydrophobic effect Effects 0.000 claims description 5
238000010348 incorporation Methods 0.000 claims description 5
239000006166 lysate Substances 0.000 claims description 5
108020004707 nucleic acids Proteins 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
206010005003 Bladder cancer Diseases 0.000 claims description 4
101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
230000002458 infectious effect Effects 0.000 claims description 4
201000005112 urinary bladder cancer Diseases 0.000 claims description 4
201000005102 vulva cancer Diseases 0.000 claims description 4
208000017667 Chronic Disease Diseases 0.000 claims description 3
208000032612 Glial tumor Diseases 0.000 claims description 3
206010018338 Glioma Diseases 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
210000001072 colon Anatomy 0.000 claims description 3
210000003128 head Anatomy 0.000 claims description 3
210000004072 lung Anatomy 0.000 claims description 3
208000026037 malignant tumor of neck Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
210000003739 neck Anatomy 0.000 claims description 3
210000001672 ovary Anatomy 0.000 claims description 3
210000002307 prostate Anatomy 0.000 claims description 3
210000003905 vulva Anatomy 0.000 claims description 3
208000003174 Brain Neoplasms Diseases 0.000 claims description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
210000003932 urinary bladder Anatomy 0.000 claims 1
239000000203 mixture Substances 0.000 description 93
210000004027 cell Anatomy 0.000 description 51
241000699670 Mus sp. Species 0.000 description 44
238000009472 formulation Methods 0.000 description 39
239000000243 solution Substances 0.000 description 35
238000000034 method Methods 0.000 description 31
102000001301 EGF receptor Human genes 0.000 description 24
235000018102 proteins Nutrition 0.000 description 23
108060006698 EGF receptor Proteins 0.000 description 21
238000002360 preparation method Methods 0.000 description 21
210000004443 dendritic cell Anatomy 0.000 description 18
238000003756 stirring Methods 0.000 description 17
210000002966 serum Anatomy 0.000 description 16
239000012528 membrane Substances 0.000 description 15
239000000839 emulsion Substances 0.000 description 12
239000002158 endotoxin Substances 0.000 description 12
229920006008 lipopolysaccharide Polymers 0.000 description 12
238000002156 mixing Methods 0.000 description 12
230000000694 effects Effects 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
230000027455 binding Effects 0.000 description 9
241000894006 Bacteria Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000028993 immune response Effects 0.000 description 7
230000003053 immunization Effects 0.000 description 7
238000002649 immunization Methods 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
238000002965 ELISA Methods 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000011651 chromium Substances 0.000 description 6
230000006698 induction Effects 0.000 description 6
229940035032 monophosphoryl lipid a Drugs 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
102000002812 Heat-Shock Proteins Human genes 0.000 description 5
108010004889 Heat-Shock Proteins Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000000969 carrier Substances 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
238000003752 polymerase chain reaction Methods 0.000 description 5
239000013641 positive control Substances 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
230000036755 cellular response Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000002434 immunopotentiative effect Effects 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
238000010255 intramuscular injection Methods 0.000 description 4
239000007927 intramuscular injection Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
230000035800 maturation Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000002994 raw material Substances 0.000 description 4
239000013049 sediment Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000013598 vector Substances 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010047741 Vulval cancer Diseases 0.000 description 3
-1 aliphatic fatty acid Chemical class 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
229940001442 combination vaccine Drugs 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000004044 response Effects 0.000 description 3
241000894007 species Species 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108020000946 Bacterial DNA Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
201000010536 head and neck cancer Diseases 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
238000009521 phase II clinical trial Methods 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
238000007789 sealing Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
102100035793 CD83 antigen Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108090000746 Chymosin Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
108010041986 DNA Vaccines Proteins 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102100022297 Integrin alpha-X Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
101710175243 Major antigen Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102000017033 Porins Human genes 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
229940022005 RNA vaccine Drugs 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
102100024333 Toll-like receptor 2 Human genes 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
HEUMNKZPHGRBKR-UHFFFAOYSA-N [Na].[Cr] Chemical compound [Na].[Cr] HEUMNKZPHGRBKR-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940080701 chymosin Drugs 0.000 description 1
231100000313 clinical toxicology Toxicity 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000004041 dendritic cell maturation Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000007667 floating Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000046157 human CSF2 Human genes 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
108700021021 mRNA Vaccine Proteins 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

JP2002547529A 2000-12-06 2001-12-06 低免疫原性抗原の免疫原性を増強する医薬組成物 Expired - Lifetime JP4210519B2 (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CU20000285A CU23000A1 (es)	2000-12-06	2000-12-06	Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU167/2001		2001-07-12
CU20010167A CU23009A1 (es)	2001-07-12	2001-07-12	Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
PCT/CU2001/000010 WO2002045746A2 (es)	2000-12-06	2001-12-06	Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Publications (4)

Publication Number	Publication Date
JP2004523494A JP2004523494A (ja)	2004-08-05
JP2004523494A5 JP2004523494A5 (de)	2005-05-26
JP2004523494A6 JP2004523494A6 (ja)	2005-06-30
JP4210519B2 true JP4210519B2 (ja)	2009-01-21

Family

ID=38812545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002547529A Expired - Lifetime JP4210519B2 (ja)	2000-12-06	2001-12-06	低免疫原性抗原の免疫原性を増強する医薬組成物

Country Status (19)

Country	Link
US (1)	US7776342B2 (de)
EP (1)	EP1356822B1 (de)
JP (1)	JP4210519B2 (de)
KR (1)	KR100850473B1 (de)
CN (1)	CN1291755C (de)
AR (1)	AR031638A1 (de)
AT (1)	ATE485833T1 (de)
AU (2)	AU2002221519B2 (de)
BR (1)	BRPI0116013B8 (de)
CA (1)	CA2431188C (de)
DE (1)	DE60143363D1 (de)
DK (1)	DK1356822T3 (de)
EA (1)	EA005138B1 (de)
MX (1)	MXPA03005032A (de)
NZ (1)	NZ526282A (de)
PE (1)	PE20020572A1 (de)
UY (1)	UY27059A1 (de)
WO (1)	WO2002045746A2 (de)
ZA (1)	ZA200304411B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1367395A1 (de) *	2002-05-02	2003-12-03	B.R.A.H.M.S Aktiengesellschaft	Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
EP1358910A1 (de) *	2002-05-02	2003-11-05	B.R.A.H.M.S Aktiengesellschaft	Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
CU23257A1 (es) *	2003-02-27	2008-01-24	Centro Inmunologia Molecular	COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) *	2003-10-09	2005-11-16	Ct Ingenieria Genetica Biotech	Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (en) *	2004-05-14	2005-11-24	The United States Of America As Represented By The Secretary Department Of Health And Human Services	Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
CA2728374A1 (en) *	2008-06-17	2010-01-14	Universite Laval	Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
UY33821A (es) *	2010-12-22	2012-07-31	Bayer Animal Health Gmbh	Respuesta inmune potenciada en la especie bovina
KR101323845B1 (ko) *	2011-01-21	2013-10-31	광주과학기술원	외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) *	2011-12-27	2015-01-29	Ct De Inmunología Molecular	Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
CN111978409B (zh) *	2013-03-15	2024-01-26	因斯瑞拜奥有限公司	自组装合成蛋白
CU24299B1 (es) *	2013-08-02	2017-12-08	Centro De Inmunología Molecular	Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
US10105306B2 (en) *	2013-09-17	2018-10-23	Bestop Group Holdings Limited	Method of preparing a growth factor concentrate
HK1194912A2 (en) *	2013-09-17	2014-10-24	Bestop Group Holdings Ltd	Growth factor concentrate and the use thereof
CA2941416C (en) *	2014-03-11	2022-10-18	Universite D'aix-Marseille	A chimeric peptide that interacts with cell membrane gangliosides
WO2018166542A1 (es)	2017-03-15	2018-09-20	Centro De Inmunologia Molecular	Método para el tratamiento de pacientes con carcinomas
US12019073B2 (en) *	2017-03-15	2024-06-25	Centro De Inmunologia Molecular	Method for the treatment of patients with carcinomas
CA3076012A1 (en) *	2017-09-27	2019-04-04	L2 Diagnostics, Llc	Erbb peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer
CU24534B1 (es) *	2017-11-06	2021-07-02	Ct Inmunologia Molecular	Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) *	2017-12-27	2019-11-04	Ct Inmunologia Molecular	Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) *	2019-01-23	2019-06-11	天德悦（北京）生物科技有限责任公司	经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4857637A (en) *	1986-05-07	1989-08-15	Genentech, Inc.	Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) *	1987-02-18	1989-04-14	Ist Farmacoterapico It Spa	Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) *	1987-06-23	1998-03-10	Lowell; George H.	Immuno-potentiating systems for preparation of immunogenic materials
MX9304089A (es)	1992-07-08	1994-01-31	Schering Corp	Uso de gm-csf como una vacuna adyuvante.
CA2137638C (en) *	1993-12-09	1999-07-20	Ana M. V. Lopez	Anti gangliosides monoclonal antibodies and their use in the specific active immunotherapy of malignant tumors
US6149921A (en) *	1993-12-29	2000-11-21	Centro De Inmunologia Molecular	Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es)	1993-12-29	1996-01-31	Centro Inmunologia Molecular	Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
JP2002509114A (ja) *	1998-01-16	2002-03-26	バイオミラ・ユーエスエイ・インコーポレイテッド	膜プロテオリポソームから作製される患者特異的白血球悪性腫瘍ワクチン

2001
- 2001-11-29 PE PE2001001202A patent/PE20020572A1/es not_active Application Discontinuation
- 2001-12-05 AR ARP010105662A patent/AR031638A1/es not_active Application Discontinuation
- 2001-12-06 KR KR1020037007634A patent/KR100850473B1/ko not_active Expired - Lifetime
- 2001-12-06 CN CNB018215602A patent/CN1291755C/zh not_active Expired - Lifetime
- 2001-12-06 AU AU2002221519A patent/AU2002221519B2/en not_active Expired
- 2001-12-06 DE DE60143363T patent/DE60143363D1/de not_active Expired - Lifetime
- 2001-12-06 EP EP01999387A patent/EP1356822B1/de not_active Expired - Lifetime
- 2001-12-06 DK DK01999387.2T patent/DK1356822T3/da active
- 2001-12-06 BR BRPI0116013-3 patent/BRPI0116013B8/pt not_active IP Right Cessation
- 2001-12-06 AT AT01999387T patent/ATE485833T1/de active
- 2001-12-06 WO PCT/CU2001/000010 patent/WO2002045746A2/es not_active Ceased
- 2001-12-06 AU AU2151902A patent/AU2151902A/xx active Pending
- 2001-12-06 JP JP2002547529A patent/JP4210519B2/ja not_active Expired - Lifetime
- 2001-12-06 EA EA200300640A patent/EA005138B1/ru not_active IP Right Cessation
- 2001-12-06 UY UY27059A patent/UY27059A1/es unknown
- 2001-12-06 MX MXPA03005032A patent/MXPA03005032A/es active IP Right Grant
- 2001-12-06 US US10/003,463 patent/US7776342B2/en not_active Expired - Lifetime
- 2001-12-06 CA CA2431188A patent/CA2431188C/en not_active Expired - Lifetime
2003
- 2003-06-04 NZ NZ526282A patent/NZ526282A/en not_active IP Right Cessation
- 2003-06-05 ZA ZA200304411A patent/ZA200304411B/en unknown

Also Published As

Publication number	Publication date
AU2151902A (en)	2002-06-18
ATE485833T1 (de)	2010-11-15
US20020136735A1 (en)	2002-09-26
WO2002045746A3 (es)	2002-12-27
JP2004523494A (ja)	2004-08-05
CN1291755C (zh)	2006-12-27
CA2431188C (en)	2010-09-07
KR100850473B1 (ko)	2008-08-07
MXPA03005032A (es)	2004-09-10
DE60143363D1 (de)	2010-12-09
UY27059A1 (es)	2002-04-26
BR0116013A (pt)	2004-01-06
PE20020572A1 (es)	2002-07-31
EA200300640A1 (ru)	2003-12-25
AR031638A1 (es)	2003-09-24
BRPI0116013B1 (pt)	2018-07-24
CN1484532A (zh)	2004-03-24
AU2002221519B2 (en)	2006-11-23
US7776342B2 (en)	2010-08-17
EP1356822A2 (de)	2003-10-29
DK1356822T3 (da)	2011-02-07
HK1063726A1 (en)	2005-01-14
NZ526282A (en)	2005-01-28
WO2002045746A2 (es)	2002-06-13
KR20030061838A (ko)	2003-07-22
EA005138B1 (ru)	2004-12-30
BRPI0116013B8 (pt)	2021-05-25
ZA200304411B (en)	2004-07-29
CA2431188A1 (en)	2002-06-13
EP1356822B1 (de)	2010-10-27

Legal Events

Date	Code	Title	Description
2004-10-15	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041014
2007-12-19	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218
2008-03-19	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080318
2008-03-27	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080326
2008-04-16	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080415
2008-04-23	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080422
2008-05-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080519
2008-07-07	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080704
2008-09-03	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080902
2008-09-24	TRDD	Decision of grant or rejection written
2008-09-29	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080926
2008-10-02	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2008-10-30	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081027
2008-10-31	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4210519 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2008-11-06	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20111031 Year of fee payment: 3
2011-07-14	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20111031 Year of fee payment: 3
2011-07-19	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20121031 Year of fee payment: 4
2011-07-19	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2012-07-24	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20131031 Year of fee payment: 5
2012-07-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2013-07-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-07-15	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-07-14	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-07-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-07-18	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-07-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-07-23	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-07-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-09-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-12-06	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JP4210519B2 (ja)	2009-01-21	低免疫原性抗原の免疫原性を増強する医薬組成物
JP2004523494A6 (ja)	2005-06-30	低免疫原性抗原の免疫原性を増強する医薬組成物
JP5519477B2 (ja)	2014-06-11	Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US12280109B2 (en)	2025-04-22	Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
CN102172397A (zh)	2011-09-07	树突细胞的体内靶向
WO2002034287A2 (en)	2002-05-02	Therapeutic vaccine formulations containing chitosan
US20050063952A1 (en)	2005-03-24	Immunogenic CEA
US20040037840A1 (en)	2004-02-26	Novel therapeutic vaccine formulations
JP2023546485A (ja)	2023-11-02	Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
JP4223813B2 (ja)	2009-02-12	免疫増強特性を有するムチンペプチド
ES2353857T3 (es)	2011-03-07	Composiciones farmacéuticas que mejoran la inmunogenicidad de antígenos poco inmunogénicos.
CA2552271A1 (en)	2005-07-14	Proteoliposomes and its derivatives as adjuvants inducers of citotoxic response and the resultant formulations
HK1063726B (en)	2007-09-14	Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
HK40020716A (en)	2020-10-23	Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines